AzTrials
AzTrials

Diabetic RetinopathyPROGRESS10NCT04650165

10-year Progression of Diabetic Retinopathy: Identification of Signs and Surrogate Outcomes

An observational study of Diabetic Retinopathy, run by Association for Innovation and Biomedical Research on Light and Image at 1 site in Portugal.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To characterize both functionally and morphologically initial Diabetic Retinopathy (DR) stages and their progression over a period of 10 years. Read more about this study

Who is it for?
Ages 35 to 80 years
Conditions the study is for
Diabetic Retinopathy
How many people
119 participants
Where
1 sitePortugal
Study dates
1 Jun 2021to 27 Mar 2024
How long will I take part?
3 Years
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Male and female subjects older than 50 years-old with type 2 Diabetes mellitus and no Diabetic Retinopathy or mild Non-Proliferative Diabetic Retinopathy who have participated in the PROGRESS study (NCT03010397).

Who may be able to join

  • Subjects who have participated in the PROGRESS study;
  • Subjects capable of understanding the information about the study and to give their informed consent to enter the study.
  • Subjects willing and able to comply with the study

Who cannot join

  • Inadequate ocular media and/ or pupil dilatation that interfere with fundus examinations

Trial locations and contacts

1 site in 1 country.

Portugal1 site
  • AIBILI - Association for Innovation and Biomedical Research on Light and Image

    Coimbra, 3000-548

Other trials in Portugal

About this study

To characterize both functionally and morphologically initial Diabetic Retinopathy (DR) stages and their progression over a period of 10 years.

Read the detailed description

Diabetic retinopathy (DR) is the most frequent complication of diabetes mellitus and the leading cause of legal blindness in active populations of industrialized countries. Progression of DR has been up to now classified according to the ETDRS classification, based on a multicentric study that evaluated the effect of laser photocoagulation on advanced stages of DR. Although appropriate for late stages of DR, it does not grade progression well in the initial stages of the disease. Initial stages of DR require urgent characterization and their evolution should be well defined because some of the lesions are still reversible.

The early stages of DR are characterized by 4 main alterations: microaneurysms (MA) and retinal hemorrhages, represented by red dots in the fundus, blood-retinal barrier breakdown, capillary closure and damage of neuronal and glial cells of the retina. Thus, there are both microvascular changes, with endothelial cell and pericyte damage with thickening of basement membrane, and neuronal changes.

Based on previous studies, progression of DR does not occur at the same rate in all patients. Some never develop vision loss, whereas others rapidly progress to macular edema or neovascularization leading to vision loss. The understanding of the mechanisms that balance in different direction is of outmost importance. The duration of diabetes mellitus and the metabolic control are major risk factors for DR progression, but they are insufficient to explain the great variability observed in patients.

Recent data indicate that MA turnover may be an appropriate indicator of DR progression. Our research group has identified different DR progression phenotypes. Phenotype A is characterized by a low MA turnover, phenotype B characterized by increased thickness and phenotype C with predominant ischemia, with a high MA turnover. These phenotypes were defined based on MA turnover (RetmarkerDR) and on central retinal thickness (RT) measured by Optical Coherence Tomography (OCT) and the model was able to correctly identify eyes at risk of progression. 61,8-76,7% of eyes with an increase RT in the central subfield, inner and/or outer ring allowed a MA formation rate ≥ 2 and/or a MA turnover ≥ 6. More recently, some genetic variants have been linked to the different phenotypes and may explain specific progression patterns.

There is emerging evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR and that it could participate in the development of microvascular abnormalities. The understanding of the underlying mechanisms leading to neurodegeneration and the identification of the mediators between neurodegeneration and microangiopathy is essential.

The Investigators aim to understand the extent of these cell abnormalities in the initial stages of DR and to characterize their progression.

Analysis of retinal thickness using OCT offers non-invasive evaluation of retinal edema and can suggest an appropriate treatment target. The Investigators will use recent and innovative approaches as Spectral domain OCT (SD-OCT) with retinal layers segmentation to study neurodegenerative changes occurring in DR. OCT-Angiography and OCT-Leakage layer by layer analysis will be used for microvasculature and blood retinal barrier assessment.

Medical subject headings
Diabetic Retinopathy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Phenotypic classification of DR in a 5-year period

    Presence CME (Central Macular Edema) or PDR (Proliferative Diabetic Retinopathy)

    Measured: 5 years

  2. DR severity level

    Early Treatment Diabetic Retinopathy Study Research Group, grading (7 fields-CFP)

    Measured: 5 years

Secondary outcomes (7)
  1. Choroidal thickness analysis

    Choroidal thickness assessed by Enhanced Depth Imaging (EDI) SD-OCT

    Measured: 5 years

  2. Retinal thickness analysis

    Retinal thickness (RT) in central subfield, inner and outer rings, assessed by SD-OCT and using layer-by-layer segmentation

    Measured: 5 years

  3. Ellipsoid zone analysis

    Degree of integrity of the ellipsoid zone, assessed by SD-OCT

    Measured: 5 years

  4. SD- OCT- Angiography analysis

    Vessel analysis, assessed by SD-OCT OCT-Angiography

    Measured: 5 years

  5. OCT-Leakage analysis

    LOR (low optical reflectivity) ratio in central subfield, inner and outer ring for assessment of BRB breakdown, assessed by OCT-Leakage

    Measured: 5 years

  6. Retinal thickness quantification

    Retinal nerve fiber layer thickness (RNFL) and ganglion cells layer (GCL) + inner plexiform layer thickness (IPL) thickness, assessed by layer-by-layer SD-OCT

    Measured: 5 years

  7. mfERG assessement

    P1 implicit time and P1 amplitude by ring

    Measured: 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Dec 2020
  2. Study start1 Jun 2021
  3. Primary completion27 Mar 2024
  4. Study completion27 Mar 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
119 participants (actual)
Target duration
3 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT04650165
Sponsor's protocol ID
CEC/011/20
Acronym
PROGRESS10
Status last verified
Oct 2024
First submitted
25 Nov 2020
Last updated
16 Oct 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetic Retinopathy, run by Association for Innovation and Biomedical Research on Light and Image at 1 site in Portugal.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 16 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Portugal. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Phenotypic classification of DR in a 5-year period (time frame: 5 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in